JO3149B1 - تراكيب وطرق إستعمال للأجسام المضادة العلاجية - Google Patents

تراكيب وطرق إستعمال للأجسام المضادة العلاجية

Info

Publication number
JO3149B1
JO3149B1 JOP/2009/0267A JOP20090267A JO3149B1 JO 3149 B1 JO3149 B1 JO 3149B1 JO P20090267 A JOP20090267 A JO P20090267A JO 3149 B1 JO3149 B1 JO 3149B1
Authority
JO
Jordan
Prior art keywords
compositions
methods
antibodies
therapeutic antibodies
baffr
Prior art date
Application number
JOP/2009/0267A
Other languages
English (en)
Inventor
Schaadt Eveline
Neugebauer Julia
Urlinger Stefanie
Heusser Christoph
Woisetschlaeger Maximilian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3149(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3149B1 publication Critical patent/JO3149B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الإختراع الحالي بالأجسام المضادة التي ترتبط بشكل محدد إلى مستقبل BAFF (BAFFR). الإختراع يتعلق بشكل محدد بأجسام مضادة محددة حيث ضواد BAFFR هى نشاط يستنفذ خلية B داخل الجسم وتراكيب وطرق إستعمال للأجسام المضادة المذكورة لمعالجة الاضطرابات الباثولوجية التي يمكن أن تعالج بقتل أو إستنفاذ خلايا B، مثل داء الذئبة الشامل الحامومى أو إلتهاب مفاصل روماتزمي أو أمراض ذاتية المناعة أخرى أو ورم غدد لمفاوية ، لوكيميا وورم نقيي myelomas.
JOP/2009/0267A 2008-07-17 2009-07-16 تراكيب وطرق إستعمال للأجسام المضادة العلاجية JO3149B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15

Publications (1)

Publication Number Publication Date
JO3149B1 true JO3149B1 (ar) 2017-09-20

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0267A JO3149B1 (ar) 2008-07-17 2009-07-16 تراكيب وطرق إستعمال للأجسام المضادة العلاجية

Country Status (40)

Country Link
US (3) US8106163B2 (ar)
EP (1) EP2315780B8 (ar)
JP (2) JP5767109B2 (ar)
KR (2) KR101314369B1 (ar)
CN (1) CN102119174B (ar)
AR (1) AR072749A1 (ar)
AU (1) AU2009272771B2 (ar)
BR (1) BRPI0915928B8 (ar)
CA (1) CA2730063C (ar)
CL (1) CL2011000086A1 (ar)
CR (1) CR11863A (ar)
CU (1) CU23878B1 (ar)
CY (1) CY1116800T1 (ar)
DK (1) DK2315780T3 (ar)
DO (1) DOP2011000016A (ar)
EA (1) EA024492B1 (ar)
EC (1) ECSP11010761A (ar)
ES (1) ES2547270T3 (ar)
GE (1) GEP20146129B (ar)
HR (1) HRP20151227T1 (ar)
HU (1) HUE025778T2 (ar)
IL (1) IL210485A (ar)
JO (1) JO3149B1 (ar)
MA (1) MA32481B1 (ar)
MX (1) MX2011000616A (ar)
MY (1) MY158980A (ar)
NI (1) NI201100017A (ar)
NZ (1) NZ590057A (ar)
PE (1) PE20110563A1 (ar)
PL (1) PL2315780T3 (ar)
PT (1) PT2315780E (ar)
RS (1) RS54299B1 (ar)
SG (1) SG193805A1 (ar)
SI (1) SI2315780T1 (ar)
SM (1) SMP201100010B (ar)
SV (1) SV2011003807A (ar)
TW (1) TWI508742B (ar)
UY (1) UY31987A (ar)
WO (1) WO2010007082A1 (ar)
ZA (1) ZA201008952B (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
ES2989943T3 (es) * 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
AU2017204936B2 (en) 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome
EP4628094A3 (en) * 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
BR112020024074A2 (pt) * 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
US20220220210A1 (en) * 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
KR20220093347A (ko) 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
WO2022031568A1 (en) 2020-08-04 2022-02-10 Novartis Ag Treatment of cll
AU2021320129B2 (en) 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
IL302412A (en) * 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
TW202302147A (zh) 2021-05-04 2023-01-16 瑞士商諾華公司 使用抗baffr抗體治療狼瘡腎炎
IL308044A (en) 2021-05-04 2023-12-01 Novartis Ag Treatment of systemic lupus erythematosus using antibuffer antibodies
AR127163A1 (es) * 2021-09-29 2023-12-27 Dragonfly Therapeutics Inc Anticuerpos dirigidos a baff-r y uso de estos
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2025058962A1 (en) * 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en) 2023-12-19 2025-06-26 Basf Se Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100447244C (zh) * 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
KR20110020914A (ko) 2011-03-03
CA2730063C (en) 2017-04-18
US20120195913A1 (en) 2012-08-02
MX2011000616A (es) 2011-02-24
AU2009272771B2 (en) 2012-09-20
IL210485A0 (en) 2011-03-31
HK1150839A1 (en) 2012-01-13
DK2315780T3 (en) 2015-10-19
EP2315780A1 (en) 2011-05-04
CN102119174B (zh) 2015-01-21
MA32481B1 (ar) 2011-07-03
SV2011003807A (es) 2011-03-23
EA201100191A1 (ru) 2011-08-30
BRPI0915928A2 (pt) 2015-11-03
NZ590057A (en) 2012-08-31
JP6077587B2 (ja) 2017-02-08
CN102119174A (zh) 2011-07-06
EP2315780B1 (en) 2015-08-19
PT2315780E (pt) 2015-11-30
DOP2011000016A (es) 2011-02-15
EP2315780B8 (en) 2015-09-23
JP2011527896A (ja) 2011-11-10
PE20110563A1 (es) 2011-08-29
RS54299B1 (sr) 2016-02-29
HRP20151227T1 (hr) 2015-12-18
TW201006493A (en) 2010-02-16
AR072749A1 (es) 2010-09-15
ECSP11010761A (es) 2011-02-28
KR101545795B1 (ko) 2015-08-19
KR101314369B1 (ko) 2013-10-10
BRPI0915928B8 (pt) 2021-05-25
UY31987A (es) 2010-02-26
IL210485A (en) 2015-03-31
ES2547270T3 (es) 2015-10-05
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
AU2009272771A1 (en) 2010-01-21
BRPI0915928B1 (pt) 2020-10-20
EA024492B1 (ru) 2016-09-30
CU20110013A7 (es) 2012-06-21
JP5767109B2 (ja) 2015-08-19
US9340620B2 (en) 2016-05-17
CA2730063A1 (en) 2010-01-21
HUE025778T2 (en) 2016-05-30
GEP20146129B (en) 2014-08-11
KR20130098432A (ko) 2013-09-04
CL2011000086A1 (es) 2011-07-01
CY1116800T1 (el) 2017-03-15
JP2015133983A (ja) 2015-07-27
CR11863A (es) 2011-02-11
TWI508742B (zh) 2015-11-21
SG193805A1 (en) 2013-10-30
NI201100017A (es) 2012-08-17
MY158980A (en) 2016-11-30
ZA201008952B (en) 2012-01-25
US8106163B2 (en) 2012-01-31
SMP201100010B (it) 2011-09-09
SI2315780T1 (sl) 2015-11-30
CU23878B1 (es) 2013-04-19
US9382326B2 (en) 2016-07-05
WO2010007082A1 (en) 2010-01-21
PL2315780T3 (pl) 2016-01-29
US20100021452A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
JO3149B1 (ar) تراكيب وطرق إستعمال للأجسام المضادة العلاجية
EP2322557A3 (en) Compositions and methods for treating proliferative disorders
JOP20180019A1 (ar) بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
MX380755B (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
PH12014502698A1 (en) Improved antagonist antibodies against gdf-8 and uses therefor
IN2012DN02702A (ar)
IN2012DN00754A (ar)
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
IN2012DN06588A (ar)
NZ626973A (en) Heterocyclic compounds and methods for their use
TN2010000599A1 (en) Compositions and methods of use for therapeutic antiodies
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
CO6341571A2 (es) Composiciones y metodos de uso para anticuerpos terapeuticos
HK1193024A (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases